Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic
- 23 December 1999
- journal article
- letter
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (1) , 22-26
- https://doi.org/10.1021/jm990446u
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Development and Characterization of a Human In Vitro Resorption Assay: Demonstration of Utility Using Novel Antiresorptive AgentsJournal of Bone and Mineral Research, 1999
- The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical developmentJournal of Clinical Investigation, 1999
- αvβ3 Integrin Binding Affinity and Specificity of SM256 in Various SpeciesJournal of Cardiovascular Pharmacology, 1999
- Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonistJournal of Clinical Investigation, 1999
- Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) AntagonistsJournal of Medicinal Chemistry, 1997
- Solid-phase synthesis of a selective αvβ3 integrin antagonist libraryBioorganic & Medicinal Chemistry Letters, 1997
- A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.Journal of Clinical Investigation, 1997
- Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.Journal of Clinical Investigation, 1995
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts*1Experimental Cell Research, 1991